Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Boetsch · SciRah

Researcher profile · Semantic Scholar

C. Boetsch

Share profile

C. Boetsch — researcher profile on SciRah

h-index: 15
Works: 53
Citations: 782

Most-cited papers

CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity
I. Solomon, M. Amann, A. Goubier, F. Vargas +28 more
2020Nature Cancer173 citations Open access
Semantic Scholar
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
M. Hidalgo, M. Martínez-García, C. le Tourneau, C. Massard +19 more
2017Clinical Cancer Research69 citations Open access
Semantic Scholar
Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
B. Ribba, C. Boetsch, T. Nayak, H. Grimm +8 more
2018Clinical Cancer Research66 citations
Semantic Scholar
The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
J. Bendell, T. Saurí, A. C. Gracián, R. Álvarez +22 more
2019The Oncologist44 citations Open access
Semantic Scholar
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies
G. Leclercq, H. Haegel, A. Schneider, A. Giusti +11 more
2021Journal for ImmunoTherapy of Cancer39 citations Open access
Semantic Scholar
Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).
M. M. Soerensen, W. Ros, M. Rodriguez Ruiz, D. Robbrecht +13 more
201837 citations
Semantic Scholar
Physiologically Based Absorption Modelling to Predict the Impact of Drug Properties on Pharmacokinetics of Bitopertin
N. Parrott, D. Hainzl, Emmanuel Scheubel, S. Krimmer +3 more
2014AAPS Journal30 citations Open access
Semantic Scholar
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
N. Steeghs, C. Gomez-Roca, K. Rohrberg, M. Mau-Sørensen +15 more
2024Clinical Cancer Research26 citations Open access
Semantic Scholar
Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers
C. Hofmann, F. Pizzagalli, C. Boetsch, D. Alberati +5 more
2016Psychopharmacology26 citations
Semantic Scholar
Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.
A. Italiano, L. Verlingue, H. Prenen, E. Guerra +16 more
202120 citations
Semantic Scholar
Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v).
I. Melero, E. Álvarez, M. Mau-Sørensen, U. Lassen +14 more
2018Annals of Oncology19 citations Open access
Semantic Scholar
GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma
T. Phillips, M. Matasar, T. Eyre, E. Giné +7 more
2023Blood18 citations Open access
Semantic Scholar
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma
L. Verlingue, A. Italiano, H. Prenen, E. G. Guerra Alía +28 more
2024EBioMedicine17 citations Open access
Semantic Scholar
Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs
L. Hutchinson, H. Mueller, E. Gaffney, P. Maini +5 more
2016CPT: Pharmacometrics & Systems Pharmacology17 citations Open access
Semantic Scholar
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
V. Gambardella, M. Ong, M. Rodriguez Ruiz, J. Machiels +24 more
2025Cancer Research Communications16 citations Open access
Semantic Scholar
Abstract 2270: RG7769 (PD1-TIM3), a novel heterodimeric avidity-driven T cell specific PD-1/TIM-3 bispecific antibody lacking Fc-mediated effector functions for dual checkpoint inhibition to reactivate dysfunctional T cells
L. C. Deak, S. Seeber, M. Perro, P. Weber +25 more
2020Immunology14 citations
Semantic Scholar
Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer.
H. Prenen, S. Deva, B. Keam, Colin R Lindsay +25 more
2024Clinical Cancer Research13 citations Open access
Semantic Scholar
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
S. Peters, E. Angevin, T. Alonso-Gordoa, K. Rohrberg +21 more
2024Clinical Cancer Research12 citations
Semantic Scholar
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
Prathap Nagaraja Shastri, Nirav Shah, M. Lechmann, H. Mody +16 more
2024Clinical pharmacology and therapy12 citations
Semantic Scholar
Effects of Cytochrome P450 3A4 Inhibitors—Ketoconazole and Erythromycin—on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions
C. Boetsch, N. Parrott, S. Fowler, A. Poirier +4 more
2016Clinical Pharmacokinetics11 citations
Semantic Scholar
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes
Jiawen Zhu, A. Schroeder, Sabine Frank, C. Boetsch +9 more
2025Clinical pharmacology and therapy10 citations Open access
Semantic Scholar
Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).
J. Pérez-Gracia, A. Hansen, R. Eefsen, C. Gomez-Roca +16 more
202110 citations
Semantic Scholar
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Aaron R. Hansen, C. Gomez-Roca, D. Robbrecht, L. Verlingue +20 more
2024Clinical Cancer Research8 citations Open access
Semantic Scholar
Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg‐Depleting Antibody
Sara Belli, M. Amann, L. Hutchinson, Laurène Pousse +10 more
2024Clinical pharmacology and therapy8 citations
Semantic Scholar
1181PPharmacokinetics (PK) and Pharmacodynamics (PD) of cergutuzumab amunaleukin (CA), a carcinoembryonic antigen (CEA)-targeted interleukin 2 variant (IL2v) with abolished binding to CD25
E. van Brummelen, U. Lassen, I. Melero, J. Tabernero +12 more
20178 citations Open access
Semantic Scholar
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
E. Muñoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V. Long +23 more
2025Cancer Research Communications7 citations Open access
Semantic Scholar
942PDVanucizumab (VAN) in combination with atezolizumab (ATEZO) for platinum-resistant recurrent ovarian cancer (PROC): Results from a single arm extension phase of the phase I study BP28179
A. Oaknin, I. Vergote, I. Ray-Coquard, A. Leary +16 more
20177 citations Open access
Semantic Scholar
Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies
Apolline Lefèvre, Z. Parra-Guillén, I. Trocóniz, C. Boetsch +1 more
2025Frontiers in Immunology6 citations Open access
Semantic Scholar
653 Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release
G. Leclercq, H. Haegel, A. Schneider, E. Berger +5 more
20205 citations Open access
Semantic Scholar
Single agent vanucizumab (RO5520985) for platinum (Pt)-resistant recurrent ovarian cancer (OC): Results from a single arm extension phase of the phase I FIH study.
A. Oaknin, A. Floquet, C. le Tourneau, I. Ray-Coquard +12 more
20155 citations
Semantic Scholar
Abstract 4553: The CD25 antibody RG6292 selectively depletes Tregs while preserving IL-2 signaling and CTL activity for tumor control
M. Amann, G. Schnetzler, K. Theresa, I. Solomon +19 more
2020Immunology4 citations
Semantic Scholar
Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers
C. Hofmann, F. Pizzagalli, C. Boetsch, D. Alberati +5 more
2016Psychopharmacology3 citations
Semantic Scholar
FAP-Targeted LTBR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumours.
Roberta Bianchi, Leo Kunz, R. Hosse, Michelle Brydon +23 more
2026Clinical Cancer Research2 citations
Semantic Scholar
Translational strategy to support the first-in-human study of a TCR-like T cell bispecific with an in vitro-based safety approach
A. Augustin, Blandine Avignon, C. Boetsch, E. Breous-Nystrom +38 more
2026Frontiers in Immunology2 citations
Semantic Scholar
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors
U. Lassen, E. van Brummelen, I. Melero, E. Angevin +21 more
2026ESMO Open2 citations Open access
Semantic Scholar
MCL-339 GLOBRYTE: A Phase III, Open-label Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma
T. Phillips, M. Matasar, T. Eyre, Eva Evaé +7 more
2024Clinical Lymphoma, Myeloma & Leukemia2 citations
Semantic Scholar
Abstract CT110: Safety and anti-tumor activity of a novel Treg depleter RG6292, as a single agent and in combination with atezolizumab in patients with solid tumors
V. Gambardella, M. Ong, M. R. Ruiz, J. Machiels +21 more
2023Cancer Research2 citations
Semantic Scholar
906P Simlukafusp α and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck
A. Hansen, C. Gomez-Roca, M. Lolkema, L. Verlingue +15 more
2021Annals of Oncology2 citations Open access
Semantic Scholar
Abstract 1643: Leveraging tumor size and time to death from bevacizumab (BEV) historical data to predict overall survival in ovarian cancer patients treated with vanucizumab (VAN)
A. Sostelly, K. Smart, Félix Jaminion, C. Boetsch +1 more
2018Clinical research2 citations
Semantic Scholar
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study
J. Pérez-Gracia, B. Mellado, Aaron R. Hansen, T. Alonso-Gordoa +34 more
2026Journal for ImmunoTherapy of Cancer1 citations Open access
Semantic Scholar
Abstract ND08: FAP-LTBR (RO7567132): a first-in-class bi-specific stromal immunomodulatory agonist designed to enable and enhance efficacy of cancer immunotherapies
Roberta Bianchi, Leo Kunz, Michelle Brydon, D. Speziale +11 more
2025Cancer Research1 citations
Semantic Scholar
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
I. Melero, J. Tabernero, N. Steeghs, D. Robbrecht +21 more
2025Clinical Cancer Research1 citations Open access
Semantic Scholar
Abstract CT176: Pharmacokinetic/pharmacodynamic (PK/PD) relationships of the novel Treg depleter RG6292 in Phase Ia and Ib studies in patients with solid tumors
T. Tanos, K. Smart, V. Gambardella, K. Rohrberg +25 more
2023Cancer Research1 citations
Semantic Scholar
Effect of molecular mechanisms mediating bevacizumab (BEV) and vanucizumab (VAN) on gastrointestinal perforation: Use of artificial neural networks for integrated data analysis.
J. Wagg, O. Krieter, C. Ooi, Samuel Croset +4 more
20171 citations
Semantic Scholar
Modeling tumor size time course in platinum resistant/refractory ovarian cancer patients treated with vanucizumab.
C. Boetsch, K. Smart, B. Ribba, François Mercier +4 more
20161 citations
Semantic Scholar
31PSchedule optimization of a novel tumor-targeted IL-2 variant immunocytokine by integration of human in vivo immune cell kinetics and functional imaging
B. Ribba, C. Boetsch, T. Nayak, Z.-X. Xu +5 more
20161 citations Open access
Semantic Scholar
Poster #209 CENTRAL GLYCINE INCREASE IN RATS, MONKEYS AND HEALTHY VOLUNTEERS AFTER TWO GLYCINE REUPTAKE INHIBITORS, RG1678 AND RG7118
F. Pizzagalli, M. Martin-Facklam, C. Hofmann, C. Boetsch +5 more
20121 citations
Semantic Scholar
Poster #226 SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RG1678, A NOVEL GLYCINE REUPTAKE INHIBITOR, AFTER MULTIPLE DOSES IN HEALTHY VOLUNTEERS
M. Martin-Facklam, A. Patat, C. Hofmann, C. Boetsch +3 more
20121 citations
Semantic Scholar
Leveraging in vitro Tumor Cell Killing and Cytokine Release to Predict Cytokine Release Syndrome Associated with CD3 T-cell Bispecifics in Oncology: a Retrospective Analysis
Apolline Lefèvre, Z. Parra-Guillén, I. Trocóniz, C. Boetsch +1 more
2025AAPS Journal0 citations Open access
Semantic Scholar
Abstract 2514: Refining oncology dose selection: A framework for tailored dose optimization in the era of targeted and immunotherapies
N. Dharia, Jiawen Zhu, A. Schroeder, Sabine Frank +10 more
2025Cancer Research0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Charo×13
Invite
J. Charo — researcher profile on SciRah
V. Teichgräber×11
Invite
V. Teichgräber — researcher profile on SciRah
D. Dejardin×11
Invite
D. Dejardin — researcher profile on SciRah
Stefan Evers×8
Invite
Stefan Evers — researcher profile on SciRah

×8

Invite

A. Kraxner — researcher profile on SciRah

N. Keshelava×8

Invite

N. Keshelava — researcher profile on SciRah

Invite

S. Evers — researcher profile on SciRah

Invite

O. Krieter — researcher profile on SciRah

Invite

K. Rohrberg — researcher profile on SciRah

M. Martin-Facklam×6

Invite

M. Martin-Facklam — researcher profile on SciRah

Nassim Sleiman×6

Invite

Nassim Sleiman — researcher profile on SciRah

Volker Teichgräber×6

Invite

Volker Teichgräber — researcher profile on SciRah